Evidence map›Paper›PMID 37323578›Full record

ArticleCell reports methods2023

Longitudinal

Sergiy Chornyy, Julie A Borovicka, Davina Patel, Min-Kyoo Shin, Edwin Vázquez-Rosa, Emiko Miller, Brigid Wilson, Andrew A Pieper, Hod Dana

Abstract read
In one paragraph

Article in Cell reports methods, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Inhibiting 15-PGDH blocks blood-brain barrier deterioration and protects mice from Alzheimer's disease and traumatic brain injury.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sergiy ChornyyDepartment of Neurosciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
Julie A BorovickaDepartment of Neurosciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
Davina PatelDepartment of Neurosciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
Min-Kyoo ShinHarrington Discovery Institute, University Hospitals Cleveland Medical Center, Cleveland, OH 44106, USA.
Edwin Vázquez-RosaHarrington Discovery Institute, University Hospitals Cleveland Medical Center, Cleveland, OH 44106, USA.
Emiko MillerHarrington Discovery Institute, University Hospitals Cleveland Medical Center, Cleveland, OH 44106, USA.
Brigid WilsonDepartment of Infectious Diseases and HIV Medicine, Case Western Reserve University, School of Medicine, Cleveland, OH 44106, USA.
Andrew A PieperHarrington Discovery Institute, University Hospitals Cleveland Medical Center, Cleveland, OH 44106, USA.
Hod DanaDepartment of Neurosciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.

Funding

Chemical, Structural and Cell-Signaling Interrogation of 15-Prostanglandin Dehydrogenase in Tissue Repair and RegenerationRM1GM142002 · NIGMS · UT SOUTHWESTERN MEDICAL CENTER · PI MARKOWITZ, SANFORD D., PIEPER, ANDREW A · 2021 to 2025
$6.9M
Translational Therapeutics CoreP30AG062428 · NIA · CLEVELAND CLINIC LERNER COM-CWRU · PI LEVERENZ, JAMES BRUCE · 2019 to 2020
$5.0M
Endophenotype Network-based Approaches to Prediction and Population-based Validation of In Silico Drug Repurposing for Alzheimer's DiseaseR01AG066707 · NIA · CLEVELAND CLINIC LERNER COM-CWRU · PI Feixiong Cheng · 2020 to 2026
$4.9M
Alzheimer's MultiOme Data Repurposing: Artificial Intelligence, Network Medicine, and Therapeutics DiscoveryU01AG073323 · NIA · CLEVELAND CLINIC LERNER COM-CWRU · PI BEKRIS, LYNN, CHENG, FEIXIONG · 2021 to 2025
$4.0M
The Alzheimer's Disease Translational Data Science Training ProgramT32AG071474 · NIA · CASE WESTERN RESERVE UNIVERSITY · PI BUSH, WILLIAM S · 2021 to 2025
$1.1M
BLRD VA I01 BX005976NIA NIH HHS P30 AG062428NIA NIH HHS R01 AG066707NIA NIH HHS T32 AG071474NIA NIH HHS U01 AG073323NIGMS NIH HHS RM1 GM142002
6 · The paper itself

Abstract

Traumatic brain injury (TBI)-induced axonal degeneration leads to acute and chronic neuropsychiatric impairment, neuronal death, and accelerated neurodegenerative diseases of aging, including Alzheimer's and Parkinson's diseases. In laboratory models, axonal degeneration is traditionally studied through comprehensive postmortem histological evaluation of axonal integrity at multiple time points. This requires large numbers of animals to power for statistical significance. Here, we developed a method to longitudinally monitor axonal functional activity before and after injury

Indexed as

Brain InjuriesBrain Injuries, TraumaticNeurodegenerative DiseasesAnimalsAxonsGeniculate BodiesMiceAlzheimer’s diseaseaxonal degenerationGCaMP6-axongenetically encoded calcium indicatorsneurodegenerationParkinson’s diseasetraumatic brain injuryvisual processing

Identifiers

PMID37323578
PMCPMC10261926

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.